Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07261137 · ClinicalTrials.gov registry record · NA

Efficacy of Solventum™ Vitrebond™ Pulp Protect Liner/Base Used as a Liner/Base Under Dental Restorations

A NA study, sponsored by Solventum US.

Terminated
Registry status
NA
Development phase
5
Enrollment target

NCT07261137 is a NA study that was terminated before completion, run by Solventum US. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07261137, a NA study, was terminated before completion, sponsored by Solventum US.

TERMINATED
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

This is a clinical study evaluating a new dental product called Solventum™ Vitrebond™ Pulp Protect Liner/Base. This new product is designed to be used as a liner or base between the tooth and the dental filling, as well as for a procedure called direct pulp capping (DPC) if there is exposed pulp. Dental pulp is the part of the tooth that contains the nerves, blood vessels, and cells that keep your tooth healthy. This study will focus specifically on the liner/base application. In this study, the Solventum study product will be compared to a similar, commercially available product made by Solventum called 3M™ Vitrebond™ Plus Light Cure Glass Ionomer Liner/Base (Vitrebond Plus for short). The study will include participants who are at least 7 years old who have at least one tooth with moderate or advanced caries (tooth decay). The entire duration of the study is anticipated to be 2 years from when the first subject begins the study until the last subject completes the study. The duration of each study subject's participation will be up to 1 year consisting of an initial tooth restoration visit at baseline, a subject self-reported post-operative sensitivity assessment at 1 week reported by phone call, and in-person follow-up assessments at 1 month, 6 months, and 1 year post-restoration to confirm safety and effectiveness. The study will be partially blinded, which means that the participant and the dentist doing the assessments won't know which liner/base product is used on their tooth.

Interventions

  • DEVICE Vitrebond™ Pulp Protect Liner/Base
  • DEVICE Vitrebond™ Plus (comparator)

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2026-02-17
Est. Completion 2026-04-15
Phase NA

Sponsor

Solventum US

41 total trials

What the Registry Record Tells You About NCT07261137

The ClinicalTrials.gov registry entry for NCT07261137 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solventum US, which has 41 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Vitrebond™ Pulp Protect Liner/Base is the first listed.

NCT07261137 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07261137 about?

NCT07261137 is a clinical study titled "Efficacy of Solventum™ Vitrebond™ Pulp Protect Liner/Base Used as a Liner/Base Under Dental Restorations". This is a clinical study evaluating a new dental product called Solventum™ Vitrebond™ Pulp Protect Liner/Base. This new product is designed to be used as a liner or base between the tooth and the dental filling, as well as for a procedure called direct pulp capping (DPC) if there is exposed pulp. De...

What is the current status of trial NCT07261137?

This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2026-02-17. Estimated completion is 2026-04-15.

What interventions are being tested in trial NCT07261137?

The interventions under investigation include: Vitrebond™ Pulp Protect Liner/Base (DEVICE), Vitrebond™ Plus (comparator) (DEVICE).

Who is sponsoring clinical trial NCT07261137?

This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.